Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

NeoGenomics Introduces Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at the American Society of Clinical Oncology
byBenzinga Newsdesk
May 28, 2024
1 minute read
Total
0
Shares
0
0
0
0
0
0

NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) conference in Chicago, May 31–June 4 (booth #31093).

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

TEGNA Sees Q4 Revenue Down Mid-To-High Teens Percent; Expects To Be Disproportionately Impacted By Cyclical Odd-To-Even Year Results Due To The Absence Of $179M Of High-Margin Political Revenue Reported In Q4 Of 2022

By Benzinga Newsdesk
November 7, 9:05 AM
FOURTH QUARTER AND FULL-YEAR 2023 OUTLOOKIn the fourth quarter of 2023, TEGNA expects to be disproportionately impacted by cyclical odd-to-even year results due to the absence of $179 million of high-margin political

TGNA